Close Menu

digital PCR

Droplet digital PCR is no better than real-time PCR at detecting and quantifying low levels of cell-associated HIV-1 genetic material from samples taken from patients both on and off antiviral therapy, according to newly published study.

NEW YORK (GenomeWeb News) – Mizuho Securities has initiated coverage of Fluidigm and BG Medicine, placing a Buy rating on both firms.

Researchers in the Department of Genetics at the Harvard University Medical School have been awarded $500,000 by the National Institutes of Health for the first year of a four-year project to study multi-allelic copy number variation in the human genome.

Bio-Rad this week reported a 4 percent drop in second-quarter revenues for its Life Sciences segment, which includes its traditional endpoint and real-time PCR products as well as its digital PCR products acquired last year along with QuantaLife.

NEW YORK (GenomeWeb News) – Funding expectations for 2013 have improved among genomics researchers, despite potential delays or cuts to budgets, according to the latest survey conducted by Mizuho Securities in collaboration with GenomeWeb.

With the market for digital PCR poised for growth over the next several years, led by established life science tool vendors such as Fluidigm, Life Technologies, RainDance Technologies, and Bio-Rad, one small startup is looking to put a new spin on the technique — literally — whil

This article has been updated from a previous version to correct the list price of the QX100 system.

Fluidigm's product revenues are expected to grow 27 percent annually over the next four years, buoyed by the company's participation in three rapidly growing niche markets — sample preparation for next-gen sequencing, single-cell genomics, and digital PCR — according to a market

Just ahead of announcing its first-quarter financial results, Fluidigm this week disclosed the end of one partnership and the beginning of another, with the net result being a de-emphasis of its digital PCR technology for molecular diagnostics and a continued emphasis on single-c

NEW YORK (GenomeWeb News) – Fluidigm today announced its collaboration with Novartis to develop a non-invasive fetal diagnostic test has ended.

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.